65th ASH Annual Meeting & Exposition: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas

Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies Oral and Poster Abstracts
Oral

Research, clinical trials, Biological therapies, Translational Research, Lymphomas, non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies

Room 6A (San Diego Convention Center)

Moderators:

Melody Smith, MD, MS, Stanford University and Damian J Green, MD, Fred Hutchinson Cancer Research Center

Disclosures:

Smith: BMS: Consultancy; A28: Membership on an entity's Board of Directors or advisory committees. Green: Juno Therapeutics A BMS Company: Patents & Royalties, Research Funding; Seattle Genetics: Consultancy, Research Funding; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy; Ensoma: Consultancy; Janssen Biotech: Consultancy, Research Funding; SpringWorks Therapeutics: Research Funding; Sanofi: Research Funding; Cellectar Biosciences: Research Funding.

4:30 PM

1021

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengass, MD, PhD¹, Adam D. Cohen, MD², Mounzer E Agha³, Michel Delforge⁴^*, Tessa Kerre⁵^*, Wilfried Roeloffzen, MD, PhD⁶^*, Hermann Einsele, MD, PhD⁷^*, Hartmut Goldschmidt⁸, Katja Weisel, MD⁹, Marc S. Raab¹⁰^*, Christof Scheid¹¹^*, Sebastien Anguille¹²^*, Pieter Sonneveld, MD, PhD¹³, Sonja Zweegman, MD, PhD¹⁴, Jordan M. Schecter¹⁵, Kevin C De Braganca¹⁵, Carolyn Chang Jackson¹⁵, Philip Vlummens¹⁶^*, Helen Varsos¹⁵^*, Christina Corsale¹⁵^*, Deepu Madduri¹⁵^*, Tzu-min Yeh¹⁵^*, Pankaj Mistry¹⁷^*, Tito Roccia¹⁸^*, Qingxuan Song¹⁵^*, Muhammad Akram¹⁹^*, Octavio Costa Filho¹⁹^*, Dong Geng¹⁹^*, Yael C. Cohen²⁰^* and Niels W.C.J. Van De Donk¹⁴^*

¹Roswell Park, Buffalo, NY
²Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
³UPMC Hillman Cancer Center, Pittsburgh, PA
⁴University of Leuven, Leuven, Belgium
⁵Ghent University Hospital, Ghent, Belgium
⁶University Medical Center Groningen, Groningen, Netherlands
⁷Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
⁸Internal Medicine V, GMMG - Study Group at University Hospital Heidelberg, Heidelberg, Germany
⁹University Medical Center Hamburg-Eppendorf, Hamburg, Germany
¹⁰University Hospital Heidelberg and Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany
¹¹University of Cologne, Cologne, Germany
¹²Vaccine and Infectious Disease Institute, University of Antwerp, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
¹³Erasmus MC Cancer Institute, Rotterdam, Netherlands
¹⁴Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
¹⁵Janssen Research & Development, Raritan, NJ
¹⁶Janssen Research & Development, Beerse, Belgium
¹⁷Janssen Research & Development, High Wycombe, United Kingdom
¹⁸Janssen Global Services, Raritan, NJ
¹⁹Legend Biotech USA Inc., Somerset, NJ
²⁰Tel -Aviv Sourasky (Ichilov) Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

4:45 PM

1022

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du¹, Wanting Qiang¹^*, Jing LU, MD¹^*, Yanchun Jia¹^*, Haiyan He¹^*, Jin Liu¹^*, Pei Guo¹^*, Ying Yang¹^*, Zhongyuan Feng¹^*, Lina Jin¹^*, Xiaoqiang Fan¹^*, Jia Liu²^*, Qi Zhang³^*, Lianjun Shen²^*, Lihong Weng²^*, Wenling Li²^* and Wei Cao²^*

¹Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Shanghai, China
²Gracell Biotechnologies Ltd., Shanghai, China
³Gracell Biotechnologies Ltd., Shanghai, AL, China

5:00 PM

1023

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Matthew J. Frigault, MD, MS¹, Jacalyn Rosenblatt, MD², Binod Dhakal, MBBS³, Noopur S. Raje, MD⁴, Daniella Cook, BS⁵^*, Mahmoud Gaballa, MD⁵^*, Estelle Emmanuel-Alejandro⁶^*, Danielle Nissen⁷^*, Kamalika C Banerjee⁸^*, Anand Rotte, PhD⁸^*, Christopher R Heery, MD⁸, David Avigan, MD², Andrzej J Jakubowiak, MD, PhD⁹ and Michael R. Bishop, MD⁹

¹Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA
²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
³BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
⁴Harvard Medical School, Boston, MA
⁵Massachusetts General Hospital Cancer Center, Boston, MA
⁶Beth Israel Deaconess Medical Center, Boston, MA
⁷Medical College of Wisconsin, Milwaukee, WI
⁸Arcellx Inc, Redwood City, CA
⁹University of Chicago, Chicago, IL

5:15 PM

1024

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, MD¹, Fateeha Furqan, MBBS², Aniko Szabo, PhD²^*, Tyce Kearl, MD³^*, Anthony Zamora, PhD²^*, Jessica Neumann⁴^*, Parameswaran N. Hari, MD, MBBS⁵, Dina Schneider, PhD⁶, Walter Longo, MD⁷^*, Peiman Hematti, MD⁵, Bryon D. Johnson, PhD⁵^*, Mehdi Hamadani, MD⁸ and Timothy S. Fenske, MD¹^*

¹Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
²Medical College of Wisconsin, Milwaukee, WI
³Division of Hematology/Oncology, Medical College of Wisconsin, MIlwaukee, WI
⁴Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee
⁵Department of Medicine, Medical College of Wisconsin, Milwaukee
⁶Lentigen Technology, Inc, A Miltenyi Biotec Company, Gaithersburg, MD
⁷Medical College of Wisconsin, Division of Hematology/Oncology, Milwaukee, WI
⁸Division of Hematology and Oncology, The Medical College of Wisconsin Inc, Milwaukee, WI

5:30 PM

1025

C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up

Ping Li¹^*, Wen-Juan Yu²^*, Lili Zhou¹^*, Min Yang, MD³^*, Shiguang Ye⁴^*, Judy Zhu, MD⁵^*, Jiaqi Huang, MD, PhD⁵^*, Yan Zhang, MD⁶^*, Lanfang Li⁷^*, Jing Zhao, MD⁷^*, Kevin Zhu, BS⁸^*, Jing Li, MD⁵^*, Chengxiao Zheng, MD⁵^*, Liping Lan, MS⁵^*, Hui Wan, MD, PhD⁵^*, Yihong Yao, PhD⁹, Huilai Zhang, MD⁷^*, Daobin Zhou, MD⁶^*, Jie Jin¹⁰ and Aibin Liang, MD, PhD¹^*

¹Department of Hematology, Tongji Hospital of Tongji University, Shanghai, China
²The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
³Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China;, Hangzhou, China
⁴Tongji Hospital of Tongji University, SHANGHAI, China
⁵Cellular Biomedicine Group Inc., Shanghai, China
⁶Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
⁷Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
⁸University of Maryland, School of Medicine, Baltimore
⁹Cellular Biomedicine Group Inc., Gaithersburg, MD
¹⁰The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

5:45 PM

1026

ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety after Fractionated Initial Therapy and Booster Dose in 60 Patients with Relapsed/Refractory Multiple Myeloma

Aina Oliver Caldes, MD¹^*, Veronica Gonzalez-Calle, MD, PhD²^*, Valentín Cabañas³^*, Nieves Lopez-Muñoz⁴^*, Paula Rodriguez Otero, MD, PhD⁵^*, Juan Luis Reguera, MD⁶^*, Marta Español-Rego, MD, PhD⁷^*, Susana Inoges, MD, PhD⁵^*, Aintzane Zabaleta⁵^*, Lucia Lopez Corral, MD, PhD⁸^*, Beatriz Martin-Antonio, PhD⁹^*, Lorena Perez-Amill, PhD¹⁰^*, Bruno Paiva⁵^*, Laura Rosiñol, MD, PhD¹¹^*, Ascensión López-Díaz De Cerio⁵^*, Sergio Navarro, Biochem⁷^*, Joan Cid, MD, PhD¹⁰^*, Natalia Tovar, MD¹⁰^*, Joaquin Saez-Peñataro, MD¹⁰^*, Miriam Lopez Parra¹²^*, Eulalia Olesti, PhD¹⁰^*, Elena Guillén, MD¹⁰^*, Sara Varea, MSc¹⁰^*, Julio Delgado¹³^*, Jose Maria Sanchez Pina¹⁴^*, Anthony Battram, PhD¹⁰^*, Marta Sonia Gonzalez Perez¹⁵^*, Andres Sanchez Salinas³^*, Valentin Ortiz-Maldonado, MD¹⁰^*, Felipe Prosper, MD, PhD⁵, Manel Juan, MD, PhD¹⁶^*, Joaquin Martinez Lopez, MD, PhD¹⁷^*, Jose Maria Moraleda, MD, PhD¹⁸^*, Maria Victoria Mateos, MD, PhD⁸, Mariona Pascal, PhD¹⁹^*, Alvaro Urbano-Ispizua Sr., MD²⁰ and Carlos Fernández de Larrea¹³^*

¹Department of Haematology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain
²Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain
³Hospital Universitario Virgen de la Arrixaca., Murcia, Spain
⁴Hospital Universitario 12 de Octubre, Madrid, Spain
⁵Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada., Pamplona, Spain
⁶Hospital Universitario Virgen del Rocio. IBiS., Sevilla, Spain
⁷Department of Immunology, Hospital Clínic, Barcelona, Spain
⁸Hospital Universitario de Salamanca, IBSAL., Salamanca, Spain
⁹Instituto de Investigacion Sanitaria - Fundacion Jimenez Diaz., Madrid, Spain
¹⁰Hospital Clinic de Barcelona, IDIBAPS., Barcelona, Spain
¹¹Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
¹²Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain
¹³Hospital Clínic de Barcelona, Barcelona, Spain
¹⁴Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
¹⁵University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
¹⁶Department of Immunology, Platform of Immunotherapy Clínic-Sant Joan de Déu, Hospital Clínic, Barcelona, Spain
¹⁷Hospital Universitario 12 de Octubre., Madrid, Spain
¹⁸Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Pascual Parrilla. University of Murcia, Murcia, Spain
¹⁹Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain
²⁰Department of Hematology, Hospital Clínic, Barcelona, Barcelona, Spain

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.O1.6 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas